Springleaf Therapeutics
Boston
About Springleaf Therapeutics
SpringLeaf Therapeutics (formerly known as Entra Pharmaceuticals, Inc.) is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf's technology is based on convergent science and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Flybridge Capital Partners and North Bridge Venture Partners.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $34.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2011)
- Website: springleaftx.com
- Phone: 617-358-4927
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Canonical: https://fsome.com/organization/springleaf-therapeutics-1798210 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.